NEW YORK – A multi-lab group led by researchers at the Translational Genomic Research Institute (TGen) has built a liquid biopsy framework that analyzes fragmentation patterns in cell-free DNA (cfDNA) linked to pediatric and pancreatic cancers.
The team's non-invasive method, which analyzes fragment ends within recurrently protected regions (RPR) in cfDNA in a patient's urine sample, produced an area under the curve (AUC) of 0.89 in in terms of differentiating cancer patients from healthy subjects.